Back to search

University of York

Applications of human microdosing with accelerator mass spectrometry: assessment of ability to predict drug-drug interactions and determine the pharmacokinetics of enantiomers

Abstract

dc:description.abstract

In this thesis, new applications of microdosing were explored in two clinical trials. Methods were developed for the separation and quantification of 14C-labelled analytes in human plasma using two-dimensional HPLC and accelerator mass spectrometry (AMS). Caffeine, midazolam, tolbutamide and fexofenadine were quantified in plasma after administration of a 14C-labelled cassette microdose to human volunteers via a HPLC-AMS recovery constant method. Mean accuracy for all analytes was within 13% of the measured plasma concentration with precision of <20% CV, meeting recommended acceptance criteria for HPLC-AMS assays. Complete resolution of each analyte was demonstrated by two-dimensional HPLC. Pharmacokinetic data obtained after cassette microdose administration were in close agreement with those previously obtained after administration of therapeutic doses. Co-administration of the cassette microdose with known inhibitors of metabolism enzymes and transporters resulted in a significant (p<0.01) increase in the area under the concentration-time curve from time zero to infinity (AUC0-∞) for caffeine (x8.2), midazolam (x11.7), fexofenadine (x3.2) and tolbutamide (x1.8, p<0.05). Administration of a combined 11C and 14C-labelled verapamil microdose allowed distribution in the brain to be monitored by PET imaging, while simultaneously obtaining plasma pharmacokinetics by AMS. The separation of 14C-verapamil by two-dimensional HPLC and AMS analysis resulted in the individual pharmacokinetics of R- and S-verapamil being consistent with those reported after therapeutic doses. In addition, a significant difference in pharmacokinetic data obtained for the two enantiomers clearly showed the preferential clearance of S-verapamil. Data were accurate within 12% of the true value with precision of <18% CV. Pharmacokinetic data obtained after PET analysis were consistent with those obtained during AMS analysis, proving the concept of combining the two techniques in clinical studies and enabling maximum information to be achieved from one single study.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of York
Year dc:date.issued
2012

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Croft, M L
Advisors dc:contributor.advisor
  • Keely, BJ
  • Morris, I

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.581594

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Croft, M L. Applications of human microdosing with accelerator mass spectrometry: assessment of ability to predict drug-drug interactions and determine the pharmacokinetics of enantiomers. doctoral thesis, University of York, 2012.